Arcutis Biotherapeutics, Inc. (ARQT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US03969K1088
Arcutis Biotherapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 376.07 m USD |
| Gross profit | 339.38 m USD |
| Operating income | -12.23 m USD |
| EBIT | -2.89 m USD |
| Net income | -16.14 m USD |
| Diluted EPS – continuing operations | -0.13 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
More stocks
- Xinfengming Group Co Ltd (603225.SS)
- Zhejiang Weiming Environment Protection Co Ltd (603568.SS)
- JTEKT Corp (6473.T)
- Takara Holdings Inc (2531.T)
- MARUWA Co Ltd (5344.T)
- Core Scientific, Inc./tx (CORZ)
- Comsys Holdings Corp (1721.T)
- Vault Minerals Ltd (VAU.AX)
- Cranswick PLC (CWK.L)
- Envista Holdings Corp (NVST)
- Chipbond Technology (6147.TWO)
- State Grid Yingda Co Ltd (600517.SS)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.